Dergiler / Marmara Pharmaceutical Journal / 2017 / Cilt: 21 - Sayı: 4

Development of a validated high-performance liquid chromatographic method for the determination of Lurasidone in pharmaceuticals

Sayfa
931–937
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The validated method has been successfully applied for determination of Lurasidone in its tablets.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:A new, rapid and simple HPLC method for determination of Lurasidone in its tablets has been developed and validated.
📊
Temel Bulgular & Veri:Lurasidone and internal standard (Chlorpromazine) was separated on a Zorbax XDB C8 column (4.6 x 50 mm, 3.5 µm particle size) set at 40°C and quantified by ultraviolet detection at 230 nm.
💡
Sonuç & Katkı:The validated method has been successfully applied for determination of Lurasidone in its tablets.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

A new, rapid and simple HPLC method for determination of Lurasidone in its tablets has been developed and validated. Lurasidone and internal standard (Chlorpromazine) was separated on a Zorbax XDB C8 column (4.6 x 50 mm, 3.5 µm particle size) set at 40°C and quantified by ultraviolet detection at 230 nm. The mobile phase was phosphate buffer (pH:3, 20 mM): acetonitrile: methanol (55:10:35, v/v/v) with a flow rate of 1.2 mL/min. Retention times of Chlorpromazine and Lurasidone was 4.73 and 6.89 minutes, respectively. The method was found linear over the concentration range of 0.5-50 µg/mL Lurasidone. Limit of detection and quantification values for Lurasidone was 0.1295 and 0.4317 µg/mL, respectively. The intra- and inter day precisions were less than 2% and the mean recoveries were 100.32%, which indicated that the method was precise and accurate. All other validation parameters were found within acceptable limits. The validated method has been successfully applied for determination of Lurasidone in its tablets.

🔖

Bu Makaleye Atıf Yap

KARACA, S. A., UĞUR, D. Y. (2017). Development of a validated high-performance liquid chromatographic method for the determination of Lurasidone in pharmaceuticals. Marmara Pharmaceutical Journal, Cilt: 21 - Sayı: 4, 931–937. https://ajindex.com/articles/283637

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Validation of analytical procedures: Text and methodology, Q2(R1). Harmonized Tripartite Guideline. 2005.
  2. Patteet L, Maudens KE, Stove CP, Lambert WE, Morrens M, Sabbe B, Neels H. The use of dried blood spots for quantification of 15 antipsychotics and 7 metabolites with ultra-high performance liquid chromatography - tandem mass spectrometry. Drug Test Anal 2015; 7: 502-11.
  3. Talluri MV, Dharavath S, Kalariya PD, Prasanth B, Srinivas R. Structural characterization of alkaline and oxidative stressed degradation products of Lurasidone using LC/ESI/QTOF/ MS/MS. J Pharm Biomed Anal 2015; 105: 1-9.
  4. Chae YJ, Koo TS, Lee KR. A sensitive and selective LC-MS method for the determination of Lurasidone in rat plasma, bile, and urine. Chromatographia 2012; 75: 1117-28.
  5. Koo TS, Kim SJ, Lee J, Ha DJ, Baek M, Moon H. Quantification of Lurasidone, an atypical antipsychotic drug, in rat plasma with high-performance liquid chromatography with tandem mass spectrometry. Biomed Chromatogr 2011; 25: 1389-94.
  6. Katteboina MY, Pilli NR, Mullangi R, Seelam RR, Satla SR. LC-MS/MS assay for the determination of Lurasidone and its active metabolite, ID-14283 in human plasma and its application to a clinical pharmacokinetic study. Biomed Chromatogr 2016; 30: 1065-74.
  7. Patteet L, Maudens KE, Sabbe B, Morrens M, De Doncker M, Neels H. High throughput identification and quantification of 16 antipsychotics and 8 major metabolites in serum using ultra-high performance liquid chromatography-tandem mass spectrometry. Clin Chim Acta 2014; 429: 51-8.
  8. Patel KY, Patel SA. Development and validation of reverse phase high performance liquid chromatography method for estimation of Lurasidone hydrochloride in synthetic mixture. Int J Pharm Drug Anal 2014; 2: 169-73.
  9. Rao BK, Ramu G, Rani P, Rambabu C. Assay of Lurasidone by a stability indicating RP-HPLC method. Am J PharmTech Res 2014; 4: 449-68.
  10. Suneetha A, Manasa K, Sindhura SL. Stability indicating RPHPLC method for determination and validation of Lurasidone HCl in bulk and pharmaceutical dosage forms. J Pharm Res 2015; 1: 15-9.
  11. Ravisankar P, Rajyalakshmi G, Dasu ChD, Babu PS, Reddy PV. Novel analytical method development and validation for the quantitative analysis of Lurasidone hydrochloride in bulk and pharmaceutical dosage forms by RP-HPLC. World J Pharm Res 2014; 3: 453-66.
  12. Chhabda PJ, Balaji M, Srinivasarao V, Appa Rao KMCh. Development